- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05227274
Pålitelighetsstudie av et motorisk funksjonsmål Digitaliserte lekne fullføringsmoduler (MFM-Play)
Neuromuscular diseases include more than 200 rare disorders affecting muscles or the nervous system. Functional scales assessing motor function are tools allowing to measure the evolution of motor impairment of patients with a neuromuscular disease. They are frequently used as main outcome measures in clinical trials which are currently in full development thanks to advances in genetic and drug researches.
Among the available scales, the Motor Function Measure (MFM), a scale consisting of 32 items, had shown good metrological properties in terms of validity, reliability and sensitivity to change, regardless of the diagnosis and extent of motor impairment.
By exploring the potential of digital technologies applied to MFM, investigators created a completion module composed of animations with different playful and informative scenarios displayed on a digital tablet.
The main purpose of this project is to conduct a multicentre study to assess reliabilities of the MFM completed using the MFM-Play.
Expected benefits of this project are to improve the experience and the participation of the children to who is often imposed multiple assessments during the numerous follow-up visits of clinical trials, while maintaining good metrological properties of the MFM.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Brest, Frankrike, 29200
- Centre de référence maladies neuromusculaires Hôpital Morvan - CHRU de Brest
-
Bron, Frankrike, 69500
- Service de Rééducation Fonctionnelle Pédiatrique - L'Escale - Hôpital Femme Mère Enfant, Hospices Civils de Lyon
-
La Tronche, Frankrike, 38700
- Service de Médecine Physique et de Réadaptation Pédiatrique Hôpital Couple-Enfant CHU de Grenoble
-
Lille, Frankrike, 59000
- Centre de référence maladies neuromusculaires Hôpital Salengro CHU Lille
-
Lyon, Frankrike, 69004
- Consultation pluridisciplinaire MNM adulte Hôpital de la Croix Rousse, Groupement Hospitalier Nord HCL
-
Nantes, Frankrike, 44200
- ESEAN - APF France Handicap
-
Paris, Frankrike, 75012
- Consultation de pédiatrie- maladie neuromusculaire Hôpital Armand Trousseau APHP
-
Saint-Etienne, Frankrike, 42000
- Service de Médecine Physique et de Réadaptation Pédiatrique Hôpital Bellevue CHU Saint Etienne
-
Saint-Priest-en-Jarez, Frankrike, 42270
- Centre de référence MNM Adulte Saint Etienne - service neurologie CHU Hôpital Nord
-
Toulouse, Frankrike, 31059
- Centre de référence des maladies neuromusculaires enfants Hôpital des enfants CHU de Toulouse
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients with a follow-up in a French neuromuscular reference center
Beskrivelse
Inclusion Criteria:
- Patients with a neuromuscular disease confirmed by the clinic, electroneuromyography (ENMG), biology, muscular biopsy, or genetic
- aged ≥ 2 yo and ≤ 60 yo
- having been informed and not objecting to participating in the study (information and non-opposition of parents/holders of parental authority for minor patients)
Exclusion Criteria:
- participating in other interventional research with an exclusion period that is still ongoing or that may interfere with the results of this study
- having had surgery or illness impacting their motor function within the last 6 months
- having understanding and/or behavioral deficiencies preventing rigorous assessment
- Patient placed under legal protection (this includes guardianship, curatorship and safeguard of justice)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: OTHER
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
MFM-Play
Neuromuscular disease patients completed MFM using MFM-Play |
Patients will completed 3 MFM during the follow-up, two times using the MFM-Play, and one without the MFM-Play Delay between each MFM completion will be 1 month ± 15 days |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Intraclass correlation coefficient (ICC) for MFM total score and D1-D3 subscores
Tidsramme: 3 months
|
ICC for MFM total score and D1-D3 subscores between the two MFM Play assessments performed by different therapists ICCs for MFM total score and D1-D3 subscores between MFM Play and conventional MFM |
3 months
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 69HCL21_1088
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .